JP2015071598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015071598A5 JP2015071598A5 JP2014205331A JP2014205331A JP2015071598A5 JP 2015071598 A5 JP2015071598 A5 JP 2015071598A5 JP 2014205331 A JP2014205331 A JP 2014205331A JP 2014205331 A JP2014205331 A JP 2014205331A JP 2015071598 A5 JP2015071598 A5 JP 2015071598A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- vaccine
- antigen complex
- gag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 20
- 210000004443 dendritic cell Anatomy 0.000 claims 15
- 229960005486 vaccine Drugs 0.000 claims 11
- 101710177291 Gag polyprotein Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- -1 CD31 Proteins 0.000 claims 3
- 230000001461 cytolytic effect Effects 0.000 claims 3
- 230000013595 glycosylation Effects 0.000 claims 3
- 238000006206 glycosylation reaction Methods 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 108010045512 cohesins Proteins 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 1
- 101150075175 Asgr1 gene Proteins 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100028667 C-type lectin domain family 4 member A Human genes 0.000 claims 1
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims 1
- 102100028672 C-type lectin domain family 4 member D Human genes 0.000 claims 1
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 claims 1
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 claims 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000766908 Homo sapiens C-type lectin domain family 4 member A Proteins 0.000 claims 1
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims 1
- 101000766905 Homo sapiens C-type lectin domain family 4 member D Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 claims 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 claims 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 claims 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 108010031099 Mannose Receptor Proteins 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 claims 1
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 108010025838 dectin 1 Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8123408P | 2008-07-16 | 2008-07-16 | |
| US61/081,234 | 2008-07-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518925A Division JP5984388B2 (ja) | 2008-07-16 | 2009-07-16 | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015071598A JP2015071598A (ja) | 2015-04-16 |
| JP2015071598A5 true JP2015071598A5 (cg-RX-API-DMAC7.html) | 2015-05-28 |
| JP6109800B2 JP6109800B2 (ja) | 2017-04-05 |
Family
ID=41551022
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518925A Expired - Fee Related JP5984388B2 (ja) | 2008-07-16 | 2009-07-16 | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン |
| JP2014205331A Expired - Fee Related JP6109800B2 (ja) | 2008-07-16 | 2014-10-06 | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518925A Expired - Fee Related JP5984388B2 (ja) | 2008-07-16 | 2009-07-16 | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9109011B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2966091B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5984388B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101548143B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102625714B (cg-RX-API-DMAC7.html) |
| AP (1) | AP2011005541A0 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009270771B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0915915A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2730742C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2966091T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2685823T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL210646A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011000507A (cg-RX-API-DMAC7.html) |
| MY (1) | MY155377A (cg-RX-API-DMAC7.html) |
| NZ (3) | NZ596171A (cg-RX-API-DMAC7.html) |
| PT (1) | PT2966091T (cg-RX-API-DMAC7.html) |
| RU (2) | RU2539765C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010009346A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201100398B (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| JP2012501323A (ja) * | 2008-08-29 | 2012-01-19 | アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク | 対象の腫瘍流入領域リンパ節へのｃｄ４０アゴニストの送達 |
| CN108373509A (zh) | 2009-03-10 | 2018-08-07 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| JP5883653B2 (ja) * | 2009-03-10 | 2016-03-15 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 抗原提示細胞ターゲティング抗ウイルスワクチン |
| CA2754862C (en) | 2009-03-10 | 2019-04-02 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
| AU2010291939B2 (en) * | 2009-09-14 | 2012-11-15 | Baylor Research Institute | Vaccines directed to Langerhans cells |
| JP5628544B2 (ja) * | 2010-04-07 | 2014-11-19 | 株式会社豊田中央研究所 | クロストリジウム・サーモセラム由来のタンパク質複合体を構築するためのタンパク質及びその利用 |
| CA2798616A1 (en) | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
| CN103328005A (zh) * | 2010-08-13 | 2013-09-25 | 贝勒研究院 | 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂 |
| US20120128710A1 (en) * | 2010-11-02 | 2012-05-24 | Baylor Research Institute | Enhancement of Pathogen-Specific Memory Th17 Cell Responses |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| TW201300418A (zh) * | 2011-03-25 | 2013-01-01 | Baylor Res Inst | 用於抗ｃ型肝炎病毒免疫之組合物及方法 |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| WO2014039840A1 (en) * | 2012-09-07 | 2014-03-13 | Baylor Research Institute | Hiv vaccine compositions and methods |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| US20160296609A1 (en) | 2013-06-28 | 2016-10-13 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
| TWI733652B (zh) | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑 |
| CN105821030A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 表达α1，3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
| CN105821029A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
| US20180356398A1 (en) | 2017-06-09 | 2018-12-13 | Fujifilm Corporation | Living tissue model device, vascular wall model, vascular wall model device and method of evaluating test substance |
| JP7693189B2 (ja) | 2017-08-10 | 2025-06-17 | グッド ティー セルズ、 インコーポレイテッド | 癌治療のためのｔ細胞の活性化方法 |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CN113597430A (zh) | 2019-02-08 | 2021-11-02 | 古德T细胞有限公司 | 激活t细胞用于癌症治疗的方法 |
| KR20220004985A (ko) | 2019-03-27 | 2022-01-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Cd40 활성화 특성을 가진 재조합 단백질 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| CA3161633A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| KR20220131895A (ko) * | 2019-11-21 | 2022-09-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법 |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CA3184802A1 (en) | 2020-05-26 | 2021-12-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| US20240010739A1 (en) | 2020-11-12 | 2024-01-11 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
| GB202019879D0 (en) * | 2020-12-16 | 2021-01-27 | Ucl Business Ltd | Polypeptide |
| KR20230124672A (ko) | 2020-12-23 | 2023-08-25 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항원 제시 세포에 대한 momp vs4 항원의 표적화에 기반한클라미디아 백신 |
| MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| MX2024006003A (es) | 2021-11-17 | 2024-08-06 | Inst Nat Sante Rech Med | Vacunas universales contra el sarbecovirus. |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| KR20250080855A (ko) | 2022-10-05 | 2025-06-05 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 니파바이러스 감염에 대한 dc 표적 백신 |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3949064A (en) | 1973-10-26 | 1976-04-06 | Baxter Laboratories, Inc. | Method of detecting antigens or antibodies |
| US4174384A (en) | 1975-06-30 | 1979-11-13 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| DK8189A (da) | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU7275698A (en) * | 1998-05-01 | 1999-11-23 | Procter & Gamble Company, The | Laundry detergent and/or fabric care compositions comprising a modified antimicrobial protein |
| WO2000000156A2 (en) * | 1998-06-26 | 2000-01-06 | Trustees Of Dartmouth College | Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands |
| JP2000157282A (ja) * | 1998-11-30 | 2000-06-13 | Toyota Central Res & Dev Lab Inc | 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素 |
| BR0109455A (pt) * | 2000-03-23 | 2003-06-03 | Akzo Nobel Nv | Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| AU2002305452A1 (en) | 2001-05-08 | 2002-11-18 | Emory University | Regulating immine responses using dendritic cells |
| GB0118367D0 (en) | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
| RU2312896C2 (ru) * | 2001-09-20 | 2007-12-20 | Глаксо Груп Лимитед | Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида |
| WO2003033695A1 (fr) | 2001-10-11 | 2003-04-24 | Katakura Industries Co., Ltd. | Procede de purification de proteine fusionnee recombinee et procede de production de proteine utilisant ledit procede de purification |
| CA2468878A1 (en) * | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation |
| EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| JP2004236504A (ja) * | 2003-02-03 | 2004-08-26 | Toyota Central Res & Dev Lab Inc | 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素 |
| JP2005143444A (ja) | 2003-11-19 | 2005-06-09 | Lion Corp | キメラ酵素及び洗浄剤組成物 |
| PT1771474E (pt) * | 2004-07-20 | 2010-05-03 | Genentech Inc | Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização |
| GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| US20080063656A1 (en) | 2004-08-09 | 2008-03-13 | Emini Emilio A | Adenoviral Vector Compositions |
| MX2007005256A (es) * | 2004-11-16 | 2008-03-11 | Crucell Holland Bv | Vacunas multivalentes que comprenden vectores virales recombinantes. |
| EP1752533A1 (en) | 2005-08-12 | 2007-02-14 | Institut National de la Recherche Agronomique | Fusion proteins between plant cell-wall degrading enzymes, and their uses |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
-
2009
- 2009-07-16 WO PCT/US2009/050903 patent/WO2010009346A2/en not_active Ceased
- 2009-07-16 CN CN200980136014.3A patent/CN102625714B/zh not_active Expired - Fee Related
- 2009-07-16 MY MYPI2011000174A patent/MY155377A/en unknown
- 2009-07-16 EP EP15182056.0A patent/EP2966091B1/en active Active
- 2009-07-16 PT PT151820560T patent/PT2966091T/pt unknown
- 2009-07-16 JP JP2011518925A patent/JP5984388B2/ja not_active Expired - Fee Related
- 2009-07-16 BR BRPI0915915A patent/BRPI0915915A2/pt not_active IP Right Cessation
- 2009-07-16 EP EP18173658.8A patent/EP3388450B1/en active Active
- 2009-07-16 MX MX2011000507A patent/MX2011000507A/es active IP Right Grant
- 2009-07-16 AU AU2009270771A patent/AU2009270771B2/en not_active Ceased
- 2009-07-16 AP AP2011005541A patent/AP2011005541A0/xx unknown
- 2009-07-16 RU RU2011105119/10A patent/RU2539765C2/ru not_active IP Right Cessation
- 2009-07-16 KR KR1020137016705A patent/KR101548143B1/ko not_active Expired - Fee Related
- 2009-07-16 CA CA2730742A patent/CA2730742C/en active Active
- 2009-07-16 ES ES15182056.0T patent/ES2685823T3/es active Active
- 2009-07-16 DK DK15182056.0T patent/DK2966091T3/en active
- 2009-07-16 US US12/504,463 patent/US9109011B2/en active Active
- 2009-07-16 EP EP09798772A patent/EP2307048A4/en not_active Withdrawn
- 2009-07-16 ES ES18173658T patent/ES2890230T3/es active Active
- 2009-07-16 NZ NZ596171A patent/NZ596171A/xx not_active IP Right Cessation
- 2009-07-16 KR KR1020117003562A patent/KR20110036618A/ko not_active Ceased
- 2009-07-16 NZ NZ590628A patent/NZ590628A/en not_active IP Right Cessation
- 2009-07-16 NZ NZ594540A patent/NZ594540A/en not_active IP Right Cessation
-
2011
- 2011-01-13 IL IL210646A patent/IL210646A0/en unknown
- 2011-01-14 ZA ZA2011/00398A patent/ZA201100398B/en unknown
-
2012
- 2012-12-10 RU RU2012153053/10A patent/RU2012153053A/ru not_active Application Discontinuation
-
2014
- 2014-10-06 JP JP2014205331A patent/JP6109800B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015071598A5 (cg-RX-API-DMAC7.html) | ||
| RU2011105119A (ru) | Вич вакцина, основанная на направленности максимизированных gag и nef на дендритные клетки | |
| Idoyaga et al. | Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A | |
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| Trumpfheller et al. | The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine | |
| TW201200150A (en) | Dendritic cell immunoreceptors (DCIR)-mediated crosspriming of human CD8+ T cells | |
| CN101679508B (zh) | 基于靶向抗原至抗原呈递细胞上表达的dcir的疫苗 | |
| AU2010291939B2 (en) | Vaccines directed to Langerhans cells | |
| JP2010518024A5 (cg-RX-API-DMAC7.html) | ||
| US9885017B2 (en) | Compositions and methods to immunize against hepatitis C virus | |
| Epaulard et al. | Macrophage-and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responses | |
| TW201305193A (zh) | 靶向結核病（ｔｂ）疫苗之樹突細胞（ｄｃ） | |
| US20120121592A1 (en) | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells | |
| TW201100096A (en) | Antigen presenting cell targeted anti-viral vaccines | |
| JP2013535508A (ja) | 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント | |
| JP2013535508A5 (cg-RX-API-DMAC7.html) | ||
| JP2010518024A (ja) | 樹状細胞アシアロ糖タンパク質受容体（ｄｃ−ａｓｇｐｒ）を介して抗原提示細胞に結合する作用物質 | |
| EP3642331B1 (en) | T-cell expansion method and uses | |
| Sulczewski et al. | Conventional type 1 dendritic cells induce TH1, TH1‐like follicular helper T cells and regulatory T cells after antigen boost via DEC205 receptor | |
| Apostolico et al. | Dendritic cell targeting effectively boosts T cell responses elicited by an HIV multiepitope DNA vaccine | |
| WO2013009841A1 (en) | Subsets of antigen-presenting cells (apc's) in the human vagina and their distinct functions | |
| You et al. | Priming of Autoreactive CD8+ T Cells Is Inhibited by Immunogenic Peptides Which Are Competitive for Major Histocompatibility Complex Class I Binding | |
| Brody et al. | Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant | |
| JPWO2021239838A5 (cg-RX-API-DMAC7.html) | ||
| US10226518B2 (en) | Ubiquitinylated proteins |